Treats T. vaginalis infection in females and males. ANDA 205245, held by Somerset Therapeutics. Metronidazole.
As of Nov 21, 2026, ANDA 205245 (Metronidazole), held by Somerset Therapeutics, was first approved by FDA on Sep 23, 2015, with 6 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Symptomatic Trichomoniasis. Metronidazole tablets are indicated for the treatment of T. vaginalis infection in females and males when the presence of the trichomonad has been confirmed by appropriate laboratory procedures (wet smears and/or cultures). Asymptomatic Trichomoniasis. Metronidazole tablets are indicated in the treatment of asymptomatic T. vaginalis infection in females when the organism is associated with endocervicitis, cervicitis, or cervical erosion. Since there is evidence that presence of the trichomonad can interfere with accurate assessment of abnormal cytological smears, additional smears should be performed after eradication of the parasite.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Sep 23, 2015 | Original application | Approved | None posted |
| Metronidazole250MG · tablet;oral | Metronidazole | Rx |
| Metronidazole500MG · tablet;oral | Metronidazole | Rx |
| Oct 25, 2024 | Supplement 13Labeling · Standard review | Approved | None posted |
| Jul 8, 2024 | Supplement 12Labeling · Standard review | Approved | None posted |
| Jun 18, 2024 | Supplement 11Labeling · Standard review | Approved | None posted |
| Jun 18, 2024 | Supplement 9Labeling · Standard review | Approved | None posted |
| Aug 18, 2021 | Supplement 8Labeling · Standard review | Approved | None posted |
| Jul 29, 2019 | Supplement 4Labeling · Standard review | Approved | None posted |
| Sep 23, 2015 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters